Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 105.9% in the 3rd quarter, Holdings Channel reports. The firm owned 77,049 shares of the biopharmaceutical company’s stock after purchasing an additional 39,635 shares during the quarter. SG Americas Securities LLC’s holdings in Esperion Therapeutics were worth $127,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BOKF NA acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at about $26,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at about $28,000. CVI Holdings LLC acquired a new stake in shares of Esperion Therapeutics in the first quarter valued at about $37,000. Sivia Capital Partners LLC acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at about $44,000. Finally, National Bank of Canada FI lifted its stake in shares of Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Price Performance

NASDAQ:ESPR opened at $2.10 on Friday. The firm has a 50 day simple moving average of $1.85 and a 200-day simple moving average of $2.12. Esperion Therapeutics, Inc. has a 1-year low of $0.71 and a 1-year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to analyst estimates of $51.90 million. As a group, research analysts expect that Esperion Therapeutics, Inc. will post -0.04 EPS for the current year.

Analysts Set New Price Targets

ESPR has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Wednesday, October 2nd. StockNews.com upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Needham & Company LLC cut their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.